2032eP Net treatment benefit in ARTEMIA trial comparing OSE2101 to docetaxel in patient with non-small cell lung cancer (NSCLC): Outcomes prioritization based on investigators preferences.
Saved in:
| Title: | 2032eP Net treatment benefit in ARTEMIA trial comparing OSE2101 to docetaxel in patient with non-small cell lung cancer (NSCLC): Outcomes prioritization based on investigators preferences. |
|---|---|
| Authors: | Piedbois, P.1 (AUTHOR), Kosta, S.2 (AUTHOR), Montestruc, F.3 (AUTHOR), Buyse, M.E.2 (AUTHOR), Salvaggio, S.2 (AUTHOR), Cappuzzo, F.4 (AUTHOR), Dziadziuszko, R.5 (AUTHOR), Viteri, S.6 (AUTHOR), Pierache, A.7 (AUTHOR), Perot, S.7 (AUTHOR), Comis, S.8 (AUTHOR), Gabarre, V.9 (AUTHOR), Vasseur, B.9 (AUTHOR), Liu, S.V.10 (AUTHOR), Besse, B.11 (AUTHOR) |
| Source: | Annals of Oncology. 2025 Supplement 2, Vol. 36, pS1154-S1155. 2p. |
| Database: | Academic Search Ultimate |
| ISSN: | 09237534 |
|---|---|
| DOI: | 10.1016/j.annonc.2025.08.2654 |
